Get Started
HBV Curricula
Step 1
These independent CME/CE activities are supported by educational grants from Bristol-Myers Squibb

Gilead Sciences, Inc.



The Advanced Certificate Program in Chronic Hepatitis B Management IV
Bridging Cultural Differences to Improve HBV Treatment
in Asian and Other Diverse Communities
  1. Curriculum VII
  2. Curriculum VI
  3. Curriculum V
  4. Curriculum IV
  5. Full Course List
Co-Chairs
faculty image
Adrian M. Di Bisceglie, MD, FACP
  • Chairman, Internal Medicine
  • Chief of Hepatology
  • Saint Louis University School of Medicine
  • St. Louis, Missouri
    • faculty image
    Robert G. Gish, MD
  • Medical Director
  • Liver Transplant Program
  • Chief, Division of Hepatology and Complex GI
  • California Pacific Medical Center
  • San Francisco, California
    • Projects In Knowledge is pleased to present The Advanced Certificate Program in Chronic Hepatitis B Mangement IV: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities.

    This year's state-of-the-science curriculum features the very latest information on screening and current and emerging treatment strategies for HBV management, including new guidelines from the CDC, AASLD, and Keeffe.

    Courses are released continuously throughout the year, and all offer CME and CE credit.

    You may also access the curricula from previous years on this website. Year 3 curriculum may be accessed through the search filter on the curriculum page. Curriculum from years 1 and 2 are available in the Library.

  • Assess the importance of screening, diagnosis, and optimal treatment intervention of patients with or at risk of developing HBV through an understanding of the epidemiology, risk factors, and disease burden imposed by HBV, including cirrhosis, HCC, morbidity, and mortality.
  • Assess the impact of cultural differences on patient communication and management of HBV infection (comparing the Asian and Pacific Islander, Latino, African-American, and Caucasian communities) to bridge these differences and improve patient outcomes.
  • Assess the role of HBV DNA and other markers in determining when to treat and optimal treatment selection in HBV-infected patients with diverse ethnic backgrounds, and in evaluating on-treatment response to therapy to improve patient outcomes.
  • Evaluate the role of genotypes in determining prognosis and selection of treatment to provide HBV-infected patients with improved outcomes.
  • Integrate HBV vaccination intervention into prevention strategies to reduce the incidence and prevalence of HBV and improve patient outcomes.
  • Formulate anti-HBV treatment strategies, considering safety, efficacy, endpoints, and resistance patterns of currently available and emerging antiviral agents as well as cultural differences among patients, to improve response rates in patients with HBV infection.
  • Integrate prescribing and monitoring strategies to help prevent or reduce the emergence of resistance into individualized anti-HBV treatment plans for infected patients.
    • AASLD, Keeffe, and APASL HBV Treatment Guidelines
    • Treatments
      • (Peg)interferon
      • Oral Nucleosides/Nucleotides: Lamivudine, Adefovir, Entecavir, Telbivudine
      • Investigational Drugs: Emtricitabine, Tenofovir, Clevudine
      • Combination Therapy
    • Treatment Endpoints and Duration
    • Monitoring for Treatment Response
    • Screening for HBV (including new CDC guidelines)
    • AASLD, Keeffe, and APASL Hepatitis B virus Treatment Guidelines (including updates)
    • HBV virology and genotyping
    • Assessing At-Risk Individuals for HBV - Special Populations
    • Screening and Diagnosis in the Asian Community
    • Chronic HBV Disease Burden
    • HBV Treatment Options and Strategies
    • HBV Treatment Resistance - Detection and Management

    Target Audience

    This CME/CE activity is designed for gastroenterologists, hepatologists, infectious disease specialists, nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians, including primary care providers and oncologists, with a special interest in hepatitis B infection.

     

    Activity Goal

    The goal of this CME/CE activity is to increase clinicians’ awareness of HBV disease prevalence and diagnostic methodology within the high-risk HBV patient populations, provide current and emerging strategies for the selection of patients for treatment, educate on current treatment options, and expand on treatment management skills for HBV-infected patients.